Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 25, 2026Open Access

Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy.

View Full Paper
Ask AI
Bookmark
Share

Authors

CVConrad-Amadeus VoltinSFSarah FlossdorfLKLars Kurch

Discussion

Loading...

Member takes

Overview

Analysis assesses metabolic tumor volume as a predictor of outcomes in large B-cell lymphoma, implying improved risk assessment methods.

Key Points

  • This study aims to determine if metabolic tumor volume (MTV) can predict outcomes better than the International Prognostic Index (IPI) in patients undergoing CAR T-cell therapy for large B-cell lymphoma.
  • Sample consisted of 111 patients from 5 German hospitals and 1 Italian center who had PET imaging before therapy.
  • Metabolic tumor burden measured semiautomatically using a fixed SUV threshold of 4.0.
  • Assessment of progression-free survival (PFS) using receiver-operating-characteristic curves and Harrell C-index.
  • Comparison of MTV with IPI and evaluation of risk scores incorporating 18F-FDG-avid tumor load.
  • MTV achieved an area under the curve of 0.68 and Harrell C-index of 0.59 for predicting PFS.
  • MTV was a more accurate predictor of PFS than the IPI, which had lower performance metrics.
  • A risk model combining MTV and extranodal involvement showed the highest performance but did not surpass MTV alone.

Cite This Study

Voltin et al. (2026) studied this question.

synapsesocial.com/papers/69c37adcb34aaaeb1a67ccf0https://doi.org/10.48620/96238
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy2026 · 1 citations
  2. 2Prognostic value of positron emission tomography-derived metabolic tumor volume for the efficacy of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory non-Hodgkin lymphomas2025
  3. 3Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy2025
  4. 4Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma2025 · 14 citations
  5. 5Prognosis prediction beyond MTV using easy to calculate parameters derived from FDG-PET/CT, a pilot Study2025